Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
Individuals with schizophrenia are three times as likely to smoke cigarettes as individuals
without schizophrenia. While a great deal of research has been focused on smoking cessation
programs for healthy individuals, little attention has been directed towards developing an
effective smoking cessation treatment for schizophrenics. This project will evaluate the
effects of 0, 21 and 42 mg transdermal nicotine on smoking, urge to smoke, and nicotine
withdrawal symptoms after 5 hrs abstinence in smokers with schizophrenia and heavy-smoking
non-psychiatric control smokers.